Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.

Frederick Berro RiveraGrace Nooriza O LumbangDanielle Rose Magno GaidLinnaeus Louisse A CruzJohn Vincent MagalongNathan Ross B BantayanKyla M Lara-BreitingerMartha GulatiGeorge L Bakris

Published in: Diabetes, obesity & metabolism (2024)

Patients on GLP-1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that BP-lowering is an indirect effect of GLP-1RA and unlikely to be responsible for the benefits.

Keyphrases

body mass index
blood pressure
end stage renal disease
rheumatoid arthritis
ejection fraction
newly diagnosed
type diabetes
chronic kidney disease
weight gain
physical activity
disease activity
ankylosing spondylitis
prognostic factors
clinical trial
skeletal muscle
open label
body weight
blood glucose